by The global AI in clinical trials market size was estimated to be around US$ 1.6 billion in 2023 and is projected to reach US$ 18.82 billion by 2033, indicating a CAGR of 28% from 2024 to 2033.
Key Takeaways
- North America held the dominating share of the AI in clinical trials market in 2023.
- By offering, the services segment held the largest market share in 2023.
- By technology, the deep learning segment held the dominating market share in 2023.
- By application, the infectious disease segment dominated the market in 2023.
- By end-user, the pharmaceutical segment held the largest share of the market in 2023; the segment is observed to sustain dominance throughout the forecast period.
The AI in Clinical Trials market is experiencing a transformative surge as artificial intelligence (AI) technologies revolutionize the landscape of clinical research and development. This sector harnesses the power of advanced algorithms, machine learning, and data analytics to enhance efficiency, accuracy, and speed in various stages of clinical trials. The integration of AI not only optimizes the trial process but also opens up new possibilities for precision medicine, ultimately improving patient outcomes.
Get a Sample: https://www.precedenceresearch.com/sample/3743
Growth Factors:
The rapid growth of the AI in Clinical Trials market can be attributed to several key factors. Firstly, the increasing complexity of clinical trials demands advanced technologies to handle vast datasets and streamline decision-making processes. AI facilitates predictive analytics, enabling more informed trial designs and patient stratification. Additionally, the rising prevalence of chronic diseases and the subsequent demand for innovative therapies have accelerated the adoption of AI, as it expedites drug discovery and development
AI in Clinical Trials Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 28% |
| Global Market Size in 2023 | USD 1.6 Billion |
| Global Market Size by 2033 | USD 18.82 Billion |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Offering, By Technology, By Application, and By End-user |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Network Engineering Services Market Size Will be $97 Bn by 2033
Opportunities
Numerous opportunities abound in the AI in Clinical Trials market. The ability of AI to enhance patient recruitment, optimize trial protocols, and predict patient responses provides a significant advantage. The integration of AI-powered tools for real-time monitoring and data analysis opens avenues for adaptive trial designs, leading to more agile and cost-effective clinical studies. Collaborations between pharmaceutical companies and AI developers present further opportunities to leverage cutting-edge technologies for improved trial outcomes.
Challenges
Despite its potential, the AI in Clinical Trials market faces challenges that need to be addressed for sustainable growth. Interoperability issues between different AI platforms, data security concerns, and the need for regulatory clarity pose significant hurdles. Additionally, the reluctance of traditional stakeholders to embrace AI, coupled with the requirement for substantial investments in infrastructure and skilled personnel, presents obstacles that must be overcome to fully unlock the potential of AI in clinical trials.
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
AI in Clinical Trials Market Companies
- AiCure
- Antidote Technologies
- Deep 6 AI
- Mendel.ai
- Phesi
- Saama Technologies
- Signant Health
- Trials.ai
- Innoplexus
- IQVIA
- Median Technologies
- Medidata
Segments Covered in the Report
By Offering
- Software
- Services
By Technology
- Machine learning
- Deep learning
- Supervised
By Application
- Cardiovascular
- Metabolic
- Oncology
- Infectious diseases
By End-user
- Pharma
- Biotech
- CROs
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on AI in Clinical Trials Market
5.1. COVID-19 Landscape: AI in Clinical Trials Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global AI in Clinical Trials Market, By Offering
8.1. AI in Clinical Trials Market, by Offering, 2024-2033
8.1.1. Software
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Services
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global AI in Clinical Trials Market, By Technology
9.1. AI in Clinical Trials Market, by Technology, 2024-2033
9.1.1. Machine learning
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Deep learning
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Supervised
9.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global AI in Clinical Trials Market, By Application
10.1. AI in Clinical Trials Market, by Application, 2024-2033
10.1.1. Cardiovascular
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Metabolic
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Oncology
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Infectious diseases
10.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global AI in Clinical Trials Market, By End-user
11.1. AI in Clinical Trials Market, by End-user, 2024-2033
11.1.1. Pharma
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Biotech
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. CROs
11.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global AI in Clinical Trials Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Offering (2021-2033)
12.1.2. Market Revenue and Forecast, by Technology (2021-2033)
12.1.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.4. Market Revenue and Forecast, by End-user (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Offering (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Technology (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.5.4. Market Revenue and Forecast, by End-user (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Offering (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Technology (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.6.4. Market Revenue and Forecast, by End-user (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Offering (2021-2033)
12.2.2. Market Revenue and Forecast, by Technology (2021-2033)
12.2.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.4. Market Revenue and Forecast, by End-user (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Offering (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Technology (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.5.4. Market Revenue and Forecast, by End-user (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Offering (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Technology (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.6.4. Market Revenue and Forecast, by End-user (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Offering (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Technology (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.7.4. Market Revenue and Forecast, by End-user (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Offering (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Technology (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.8.4. Market Revenue and Forecast, by End-user (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Offering (2021-2033)
12.3.2. Market Revenue and Forecast, by Technology (2021-2033)
12.3.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.4. Market Revenue and Forecast, by End-user (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Offering (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Technology (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.5.4. Market Revenue and Forecast, by End-user (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Offering (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Technology (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.6.4. Market Revenue and Forecast, by End-user (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Offering (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Technology (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.7.4. Market Revenue and Forecast, by End-user (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Offering (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Technology (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.8.4. Market Revenue and Forecast, by End-user (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Offering (2021-2033)
12.4.2. Market Revenue and Forecast, by Technology (2021-2033)
12.4.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.4. Market Revenue and Forecast, by End-user (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Offering (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Technology (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.5.4. Market Revenue and Forecast, by End-user (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Offering (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Technology (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.6.4. Market Revenue and Forecast, by End-user (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Offering (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Technology (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.7.4. Market Revenue and Forecast, by End-user (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Offering (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Technology (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.8.4. Market Revenue and Forecast, by End-user (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Offering (2021-2033)
12.5.2. Market Revenue and Forecast, by Technology (2021-2033)
12.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.4. Market Revenue and Forecast, by End-user (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Offering (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Technology (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.5.4. Market Revenue and Forecast, by End-user (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Offering (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Technology (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.6.4. Market Revenue and Forecast, by End-user (2021-2033)
Chapter 13. Company Profiles
13.1. AiCure
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Antidote Technologies
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Deep 6 AI
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Mendel.ai
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Phesi
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Saama Technologies
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Signant Health
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Trials.ai
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Innoplexus
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. IQVIA
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
